Opera Therapeutics is Drug Discovery in United States that focus on Retinal Vein Occlusion business. Founded in 2017. They cover business area such as developer, therapeutic treatment, ocular and neurological disease, cell death, hallmark, Diabetic Macular Edema, DME, Retinal Vein Occlusion, RVO, vision loss, people, diabetes, an eye-drop, enhanced relief, patient, diabetic retinopathy, healthcare professional, an alternative form, anti-angiogenesis therapy, thromboembolic side effect.
2017
( 7 years old in 2024 )
Retinal Vein Occlusion
-
New York, NY
United States
Private
developertherapeutic treatmentocular and neurological diseasecell deathhallmarkDiabetic Macular EdemaDMERetinal Vein OcclusionRVOvision losspeoplediabetesan eye-dropenhanced reliefpatientdiabetic retinopathyhealthcare professionalan alternative formanti-angiogenesis therapythromboembolic side effect
* We use standard office opening hours in near Opera Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Opera Therapeutics is Drug Discovery business from United States that founded in 2017 (7 years old in 2024), Opera Therapeutics business is focusing on Retinal Vein Occlusion.
Opera Therapeutics headquarter office and corporate office address is located in New York, NY United States.
Opera Therapeutics was founded in United States.
In 2024, Opera Therapeutics is currently focus on Retinal Vein Occlusion sector.
Above is snippet of Google Trends for "Retinal Vein Occlusion" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Opera Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
